Risk of congenital anomalies in pregnant users of statin drugs

British Journal of Clinical Pharmacology

Volumn 64, Issue 4, 2007, Pages 496-509

  Ofori, Benjamin ^b   Rey, Evelyne ^b   Bérard, Anick ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NONE

Author keywords

Antilipademic agents; Congenital anomalies; Pregnancy; Pregnancy registry; Statins

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PRAVASTATIN; QUINIDINE; ROSUVASTATIN; SIMVASTATIN;

ADOLESCENT; ADULT; ARTICLE; CONCEPTION; CONFIDENCE INTERVAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HYPERLIPIDEMIA; LIVE BIRTH; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTILIPEMIC AGENTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; RISK FACTORS;

EID: 34548640412     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02905.x     Document Type: Article

References (34)

1. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas A, Fidanza F. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995 274 : 131 6.
2. Pearson TA. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am J Cardiol 2004 94 : 4F 8F.
3. Miller VT. Dyslipoproteinemia in women. Special considerations. Endocrinol Metab Clin North Am 1990 19 : 381 98.
4. Weinstock RS. Treating type 2 diabetes mellitus: a growing epidemic. Mayo Clin Proc 2003 78 : 411 3.
5. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 2006 174 : 1124 9.
6. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996 10 : 439 46.
7. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998 30 : 46.
8. Barss V, Phillippe M, Greene MF, Covell L. Pregnancy complicated by homozygous hypercholesterolemia. Obstet Gynecol 1985 65 : 756 7.
9. Cashin-Hemphill L, Noone M, Abbott JF, Waksmonski CA, Lees RS. Low-density lipoprotein apheresis therapy during pregnancy. Am J Cardiol 2000 86 : 1160, A10.
10. Beigel Y, Hod M, Fuchs J, Lurie J, Friedman S, Green P, Merlob P, Melamed R, Ovadia J. Pregnancy in a homozygous familial hypercholesterolemic patient treated with long-term plasma exchange. Am J Obstet Gynecol 1990 162 : 77 8.
11. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med A 2004 131 : 287 98.
12. Edison RJ, Muenke M. Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoprosencephaly. N Engl J Med 2005 352 : 2759.
13. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005 73 : 888 96.
14. Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In : Pharmacoepidemiology, 3rd edn, ed Strom BL. Toronto : John Wiley & Sons, Ltd 2000 : 151 74.
15. Régie de l'assurance maladie du Québec. Statistiques annuelles 1997.
16. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998 279 : 1458 62.
17. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000 160 : 2363 8.
18. Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997 350 : 979 82.
19. Roy E, Haley N, Leclerc P, Sochanski B, Boudreau JF, Boivin JF. Mortality in a cohort of street youth in Montreal. JAMA 2004 292 : 569 74.
20. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995 48 : 999 1009.
21. Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995 142 : 428 36.
22. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 7th edn. Philadelphia : Lippincott Williams & Wilkins 2005.
23. Rodondi KM. Hyperlipidemia. In : Textbook of Therapeutics: Drug and Disease Management, 6th edn, eds Herfindal ET, Gourley DR. London : Williams & Wilkins 1996 : 387 403.
24. Rasmussen SA, Moore CA, Paulozzi LJ, Rhodenhiser EP. Risk for birth defects among premature infants: a population-based study. J Pediatr 2001 138 : 668 73.
25. Lilienfeld D, Stolley PD. Foundations of Epidemiology, 3rd edn. New York : Oxford University Press 1994 : 302 3.
26. Bérard A, Blais L, Lelorier J. Système de Surveillance de l'Utilisation des Médicaments durant la Grossesse. Le Réseau Québecois de Recherche sur L'usage des Médicaments (RQRUM) Annual Conference, Quebec City, Quebec, Canada. 5-6 June 2006.
27. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Ottawa : Canadian Pharmacists Association 2006.
28. Regal RR, Hook EB. Interrelationships of relative risks of birth defects in embryonic and fetal deaths, in livebirths, and in all conceptuses. Epidemiology 1992 3 : 247 52.
29. Brent RL, Beckman DA. The contribution of environmental teratogens to embryonic and fetal loss. Clin Obstet Gynecol 1994 37 : 646 70.
30. Wikipedia. The Free Encyclopedia, 2006. Simpson's paradox. Available at http://en.wikipedia.org/wiki/Simpson's_paradox (last accessed : 17 October 2006).
31. Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 2001 94 : 435 44.
32. Boulot P, Chabbert-Buffet N, d'Ercole C, Floriot M, Fontaine P, Fournier A, Gillet JY, Gin H, Grandperret-Vauthier S, Geudj AM, Guionnet B, Hauguel-de-Mouzon S, Hieronimus S, Hoffet M, Jullien D, Lamotte MF, Lejeune V, Lepercq J, Lorenzi F, Mares P, Miton A, Penfornis A, Pfister B, Renard E, Rodier M, Roth P, Sery GA, Timsit J, Valat AS, Vambergue A, Verier-Mine O. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 2003 26 : 2990 3.
33. Macintosh MCM, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D, Golightly S, Miller A. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 2006 333 : 177.
34. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol 2003 188 : 1039 45.